Reviva Net Debt To E B I T D A from 2010 to 2024
| RVPHW Stock | USD 0.23 0.04 21.05% |
Net Debt To EBITDA | First Reported 2010-12-31 | Previous Quarter 0.00000059 | Current Value 0.000001 | Quarterly Volatility 5.6916501 |
Check Reviva Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Reviva Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 10 K, Net Interest Income of 523.9 K or Interest Income of 523.9 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 22.5. Reviva financial statements analysis is a perfect complement when working with Reviva Pharmaceuticals Valuation or Volatility modules.
Reviva | Net Debt To E B I T D A |
Latest Reviva Pharmaceuticals' Net Debt To E B I T D A Growth Pattern
Below is the plot of the Net Debt To E B I T D A of Reviva Pharmaceuticals Holdings over the last few years. It is a leverage ratio that indicates a company's ability to pay off its incurred debt. It compares a company's net debt (total debt minus cash) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). Reviva Pharmaceuticals' Net Debt To EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Reviva Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Debt To E B I T D A | 10 Years Trend |
|
Net Debt To E B I T D A |
| Timeline |
Reviva Net Debt To E B I T D A Regression Statistics
| Arithmetic Mean | (6.18) | |
| Geometric Mean | 0.82 | |
| Coefficient Of Variation | (92.14) | |
| Mean Deviation | 5.11 | |
| Median | (10.01) | |
| Standard Deviation | 5.69 | |
| Sample Variance | 32.39 | |
| Range | 13.7743 | |
| R-Value | 0.78 | |
| Mean Square Error | 13.78 | |
| R-Squared | 0.61 | |
| Significance | 0.0006 | |
| Slope | 0.99 | |
| Total Sum of Squares | 453.53 |
Reviva Net Debt To E B I T D A History
About Reviva Pharmaceuticals Financial Statements
Reviva Pharmaceuticals investors use historical fundamental indicators, such as Reviva Pharmaceuticals' Net Debt To E B I T D A, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Reviva Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Reviva Stock Analysis
When running Reviva Pharmaceuticals' price analysis, check to measure Reviva Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Reviva Pharmaceuticals is operating at the current time. Most of Reviva Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Reviva Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Reviva Pharmaceuticals' price. Additionally, you may evaluate how the addition of Reviva Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.